For The Better

HAS earnings call for the period ending March 31, 2022.

Plus an interview with Ron Lieber, personal finance columnist for “The New York Times” and author of “The Opposite of Spoiled: Raising Kids Who Are Grounded, Generous, and Smart About Money.”

Investors might not be giving this telehealth titan enough credit.

The company has a knack for knowing what customers will want before they want it.

Consider these all-weather plays in a stormy market.

Buying these down-but-not-out growth stocks could supercharge your portfolio.

Is Starbucks a buy as it inches closer to 52-week lows?

Hims & Hers is a young company with a bright future ahead.

Here are some pitfalls you’ll really want to steer clear of.

You should exercise caution before buying these stocks.

Investors latched on to positive comments made by an analyst.

Lululemon is an athletic apparel juggernaut.

The campus housing REIT got a deal it couldn’t refuse, and investors acted accordingly. Here’s a quick look at what you need to know.

The tech sell-off could be providing long-term investors with excellent buying opportunities.

Investors have some big questions heading into this earnings announcement.

These three companies are popular on Robinhood — and for good reason.

Which one of these two potential metaverse winners should you be betting on?

The company fired its CEO.

Abbott’s innovation and execution drive long-term success despite many moving parts.

A long-awaited FDA decision regarding AXS-05 finally has a timeline.